Postconditioning by Delayed Administration of Ciclosporin A: Implication for Donation after Circulatory Death (DCD)

René Ferrera1, Marie Védère1, Megane Lo-Grasso1

  • 1University of Lyon, CARMEN Laboratory, INSERM, INRAE, Université Claude Bernard Lyon 1, 69500 Lyon, France.

Insights

Delayed application of ciclosporin-A (CsA) effectively reduces ischemia-reperfusion injury in Donation after Circulatory Death (DCD) heart models. Unlike ischemic postconditioning, CsA maintains cardioprotection even when administered with a delay, preserving heart function and mitochondrial health.

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Cardiovascular Research

Background:

  • Graft shortage is a major limitation for heart transplantation.
  • Donation after Circulatory Death (DCD) offers a potential solution to increase organ availability.
  • Ischemia-reperfusion injury remains a significant challenge in DCD heart preservation.

Purpose of the Study:

  • To evaluate the efficacy of postconditioning strategies in mitigating ischemia-reperfusion injury in a DCD rat heart model.
  • To compare the protective effects of ischemic postconditioning (POST) versus ciclosporin-A (CsA) treatment.
  • To determine the impact of delayed application of these interventions on cardioprotection.

Main Methods:

  • Utilized an isolated rat heart model simulating DCD conditions with 40 minutes of warm global ischemia followed by cold preservation and reperfusion.
  • Assessed outcomes in control, immediate POST, and immediate CsA groups, as well as subgroups receiving delayed POST or CsA (3, 10, 20 minutes after reperfusion onset).
  • Measured myocardial necrosis, cardiac function, mitochondrial respiratory index, and mitochondrial permeability transition pore (MPTP) opening.

Main Results:

  • Both POST and CsA significantly reduced necrosis and improved heart function compared to controls.
  • POST efficacy diminished when delayed beyond 3 minutes of reperfusion.
  • Delayed CsA administration (up to 10 minutes) effectively reduced necrosis and improved functional recovery, correlating with preserved mitochondrial function.
  • MPTP opening thresholds were similar across cardioprotected groups, implicating MPTP in delayed CsA protection.

Conclusions:

  • Delayed CsA administration provides significant cardioprotection in DCD hearts, unlike delayed ischemic postconditioning.
  • CsA's protective mechanism in delayed application appears linked to mitochondrial function and MPTP regulation.
  • This finding supports the potential of delayed CsA treatment to enhance the viability of DCD donor hearts for transplantation.